KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Share-based Compensation: 2012-2024

Historic Share-based Compensation for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $50.7 million.

  • Xenon Pharmaceuticals' Share-based Compensation rose 5.41% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.2 million, marking a year-over-year increase of 14.88%. This contributed to the annual value of $50.7 million for FY2024, which is 56.67% up from last year.
  • As of FY2024, Xenon Pharmaceuticals' Share-based Compensation stood at $50.7 million, which was up 56.67% from $32.4 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Share-based Compensation ranged from a high of $50.7 million in FY2024 and a low of $5.7 million during FY2020.
  • Its 3-year average for Share-based Compensation is $34.5 million, with a median of $32.4 million in 2023.
  • Data for Xenon Pharmaceuticals' Share-based Compensation shows a peak YoY skyrocketed of 103.41% (in 2022) over the last 5 years.
  • Xenon Pharmaceuticals' Share-based Compensation (Yearly) stood at $5.7 million in 2020, then surged by 76.45% to $10.0 million in 2021, then spiked by 103.41% to $20.4 million in 2022, then skyrocketed by 58.87% to $32.4 million in 2023, then skyrocketed by 56.67% to $50.7 million in 2024.